Meeting
2024 ASCO Annual Meeting
Comprehensive characterization of ERBB2 genomic alterations in lung cancer.
Authors
Talal El Zarif
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
Talal El Zarif , Paul Stockhammer , Jacob Schillo , Sarah B. Goldberg , Katerina A. Politi , Michael J Grant
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3148)
DOI
10.1200/JCO.2024.42.16_suppl.3148
Abstract #
3148
Poster Bd #
293
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.
First Author: Benjamin Herzberg
Poster
2022 ASCO Annual Meeting
Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.
First Author: Alessio Cortellini
Poster
2021 ASCO Annual Meeting
Genomic landscape differences in patients with advanced non-small cell lung cancer by sex and age.
First Author: ErinMarie Kimbrough
Poster
2021 ASCO Annual Meeting
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.
First Author: Chul Kim